Theralink Technologies Inc. · OTC:THER
Theralink Technologies — Investor Presentation (October 2020)
32 slides from Theralink Technologies's investor presentation, Oct 29, 2020
Slide 1: Theralink Technologies Investor Presentation
Bay aN Theralink Technologies, Inc. (OTC: OBMP) Investor Presentation Enabling Physicians to make Personalized Treatment Recommendations for Cancer Patients
Slide 2: Disclaimers
nn ——————O——O——O—O——O—O—O—OEO—OOEOEOEOEOEOOOEO—O—EOEOOEOEOEOEOEOOOOOEOEOOEOEOOEOOEOEOEOEOEOOEOEOEOEOEOEOO—E—E—EeEeEeeeeeeeeeeeereretee Disclaimers Forward Looking Statements: Certain information contained in this presentation includes forward-looking statements. The statements herein that are not hi
Slide 3: Topics
Topics 1. Theralink Technologies Overview 2. The Current State of Cancer 3. Market and Opportunity 4. Core Technology 5. Robust and Growing IP 6. Competition 7. Growth Strategy 8. Management and Leadership Team 9. 2020 Milestones 10. Investment Highlights 3 THERALINK® Precision Medicine for Uf
Slide 4: Theralink Technologies Overview
Theralink® Technologies Overview RPPA Technology Unique Intellectual Property CLIA Certified Lab Facility Large Market, Targeted Launch RPPA technology measures activated proteins, which are the primary targets of the majority of FDA-approved therapies and investigational drugs. Theralink is the onl
Slide 5: What Does Theralink's Technologies Have in Common with Institutions
What does Theralink’s Technologies Have in Common with the Following 20 Domestic and International Institutions that are Utilizing our RPPA Technology in their Basic Research? Proven Technology United States Europe Asia Pacific * 7 Commercial George Mason University Royal College of Surgeons, Irelan
Slide 6: What Makes Theralink Technologies Unique?
What Makes Theralink Technologies Unique? Theralink Technologies is the only Company that combines laser capture microdissection with patented data-generating RPPA technology to quantify active protein signaling in the cell using minimal sample input. kh Genomics Transcriptomics Proteomics Phosphopr
Slide 7: Theralink's Reverse Phase Protein Array (RPPA) Technology
a Theralink’s Reverse Phase Protein Array (RPPA) Technology Beyond Genomics...Changing the Paradigm in Cancer Treatment ¢ Developed by the founding scientists at the world-renowned Center for Applied Proteomics and Molecular Medicine at George Mason University. ¢ Theralink’s RPPA technology can meas
Slide 8: The Current State of Cancer
The Current State of Cancer * Cancer is heterogeneous and each patient’s cancer is UNIQUE. * Cancer is a disease of abnormal protein signaling, and Diagnose many therapeutic drugs target these aberrant proteins. @ 4 © = * Theralink assesses which proteins are likely driving a patient’s cancer. * Not
Slide 9: The Power of Phosphoproteomics
The Power of Phosphoproteomics > — @— @ = @ Genomics/Transcriptomics Proteomics/Phosphoproteomics The “Instructions” The “Working Machinery” * Information is not directly actionable as drugs * Information can be directly actionable as drugs target proteins, not genes or transcripts target proteins *
Slide 10: The Value of RPPA
nn ——————O——O——O—O——O—O—O—OEO—OOEOEOEOEOEOOOEO—O—EOEOOEOEOEOEOEOOOOOEOEOOEOEOOEOOEOEOEOEOEOOEOEOEOEOEOEOO—E—E—EeEeEeeeeeeeeeeeereretee The Value of RPPA For Drug Companies For Patients Accelerate drug discovery Future potential for and development advanced therapy selection for improvements in thera
Slide 11: Market Size
Market Size Number of Clinical Trials Incidence of Cancer (U.S.) U.S. Market Analysis (TAM, SAM, SOM) 12 TAM: Worldwide TAM: US cases are candidates for the Theralink® assay SAM:US breast cancer SAM: US Only 98,745 jwomer} SOM: Potentially 175,000+ Si @incen x: of these breast cancer * Theralink® co
Slide 12: Commercial Opportunity: Precision Medicine
Commercial Opportunity: Precision Medicine Future Opportunities Total Market * Match patients to trial ‘arctenea de * Help improve effectiveness & help reduce : costs 1 Billion Trial (near-term) ae $ * Potentially increase success of drug approvals * Offer treatment selection with Theralink Assay On
Slide 13: Initial Commercialization Strategy: Silos
Se Initial Commercialization Strategy: 2 Silos Theralink Business Markets 7 5 Precision Oncolo Biopharma Services . . ey/ Clinical Testing * Drug Development * Theralink validated LDT * Companion Diagnostics performed in CAP/CLIA Lab (CDx) Development s THERALINK® Note: Theralink LDTs are developed
Slide 14: Initial Commercialization Strategy: Silo 1 Biopharma Services
Initial Commercialization Strategy: Silo 1 Biopharma Services Helping drug companies accelerate discovery and development of novel cancer treatments i THERALINK® Precision Medline for Life™
Slide 15: Biopharma R&D: Our Core Technology Works Across Continuum
Biopharma R&D: Our Core Technology Works Across Continuum Lead Lead Lead : ‘ Th Thi se na Hee IND ‘Phase! Screening eeey een) ID Development J Optimization Sees Selection Monitoring Discovery Clinical Trials Patient Care ¢ Provides Biopharma companies in »* Provides Biopharma companiesin »* Provides
Slide 16: Theralink: Biopharma LCM/RPPA Workflow
Theralink: Biopharma LCM/RPPA Workflow LCM RPPA —> —> Heterogenous Tumor cells Proteins measured — > .M > Sample Prep Laser Capture Reverse Phase Antibody Probe Informatics *Tissue Microdissection Protein Array and Staining Report i THERALINK” re 16
Slide 17: Initial Commercialization Strategy: Silo 2 Precision Oncology/Clinical Testing
3 THERALINK® precision Medline for Life™ Initial Commercialization Strategy: Silo 2 Precision Oncology/ Clinical Testing May provide actionable information on activity of key drug targets in oncology Note: Theralink LDTs are developed and the performance characteristics determined by Theralink's CLI
Slide 18: Precision Oncology Care: Theralink LDT's
Precision Oncology Care: Theralink LDT’s * Theralink measures the presence and activation status of the drug targets. * While genomic analysis can reveal gene mutations, it can not directly measure the abundance of activated protein. * The drug will only work if the drug target is actively driving d
Slide 19: Theralink: LDT Workflow
aT HERALINK® Precision Medline for Lie Theralink: LDT Workflow 6 DAY 1 DAY 2 DAY 3. STEP 4- THERALINK LAB Q_ 10 day TAT begins Histology QC for tumor Laser CaptureMicrodssection Tissue lysis and Print lysates onto RPPA (' DAY 6 DAY 5 DAY 4 ) STEP 4 THERALINK Lag feo] a RE oNo 1o10 Report created Con
Slide 20: Companion Diagnostics to Advance Precision Oncology
er Companion Diagnostics to Advance Precision Oncology CDx is a Core Component of Both Business Markets * A Companion Diagnostic (CDx) is a test that must be ordered by a physician/oncologist prior to the doctor prescribing the associated drug or targeted therapy. * FDA expects contemporaneous regul
Slide 21: Benefits of Theralink
Benefits of Theralink For Biopharma Companies * Reduce clinical trial failure rates and cost. * Increase efficacy rates that can support premium pricing. For Oncologists * Potentially helps Identify treatment options. AA * May guide therapies for patients who develop resistance to treatment. f For P
Slide 22: Robust and Growing IP and Patent Portfolio
Robust and Growing IP and Patent Portfolio Patent Numb Baie Claims on all use of proteomic methods to mTOR Pathway Theralink 8,628,931 BI 1/31/2031 identify activation of MTOR pathway, known to be associated with therapy-resistant tumors. Claims on methods of use for c-erB2 to better 9,086,414 B2 3/
Slide 23: Competitive Landscape: Only Complete Proteomics Company
Competitive Landscape: Only Complete Proteomics Company Feature End User 2 Drug Target Activation Mapping Biopharma Biopharma Activated Phosphoprotein Biomarkers Quantitative Protein Biomarkers Qualitative Proteomic Markers + Oncologists Biopharma + Oncologists Biopharma + Oncologists + +++ i THERAL
Slide 24: Growth Strategy
eee Growth Strategy Biopharma Alliances: * Service and Leverage Current Clients * Sales Pipeline with numerous Global Biopharma Prospects * Recently hired Experienced Senior Director, Biopharma Commercial Operations. Continually Pursue Companion Diagnostics with Biopharmaceutical Partners. CLIA Cert
Slide 25: Growth Strategy (cont.)
er Growth Strategy (cone) * Develop and deploy an informational marketing campaign coupled with increased funding to inform pharmaceutical companies, laboratory service providers, insurers, and clinicians/oncologists and their patients of the value that the Theralink assays might offer. * Utilize ke
Slide 26: What Experts Say About The Theralink Assay
er What EXPERTS Say About The Theralink Assay “The Theralink assay allows me to understand which protein biomarkers and signaling pathways are active and driving my patients metastatic breast cancer growth. Proteomic information can be instrumental in helping guide therapy choices for my patients.”
Slide 27: Experienced Leadership: Corporate
Experienced Leadership: Corporate Jeffrey Busch, Esq., Chairman Co-founder, Chairman and CEO of Global Medical REIT, Inc. (GMRE), a NYSE listed public company. Industry leader in building and sustaining medical companies worldwide. Mr. Busch was appointed by two US Presidents to serve in their Admin
Slide 28: Experienced Leadership: Commercialization
Experienced Leadership: Commercialization Trevor McCartney Senior Director of Business Development 20+ years of cancer leadership experience working in the field of enabling technologies for cancer care Various capacities with Elekta Inc., a global provider of medical devices for the treatment of ca
Slide 29: Scientific & Pathology Advisors
a Scientific & Pathology Advisors Dr. Emanuel F. Petricoin Founder RPPA * Co-Director of the Center for Applied Proteomics and Molecular Medicine (CAPMM) at George Mason University since 2005. * Co-founder of 4 life science companies, co- authored nearly 400 publications, co-inventor on 40 filed and
Slide 30: 2020 Milestones
2020 Milestones * CLIA certification for lab achieved September 9, 2020 ¢ Planning 4 Cancer Center and Channel Partner Accounts ¢ Planning 10 Biopharma Contracts Roll out of Theralink’s Clinical Registry Trial for Reimbursement * Begin receiving patient tumor samples from Oncologists is THERALINK® N
Slide 31: Investment Highlights
Oe Investment Highlights Valuable IP portfolio (7 patents) Innovative platform technology that can be leveraged for many large market cancer indications Clear path to commercialization Experienced management team with an excellent track record Precision Ms Only Company with the commercial rights and
Slide 32: Theralink Technologies Investor Contact
Theralink Technologies Investor Contact: 15000 West 6th Ave, Valter Pinto / Allison Soss Suite 400 KCSA Strategic Communications Golden, CO 80401 Phone: (212) 896-1254 https://theralink.com Email: investors@theralink.com s@& THERALINK® ne for fe
Theralink Technologies — Investor Presentation (October 2020) on 6ix